Cargando…

Predictors of adherence and persistence to disease-modifying therapies in Multiple Sclerosis

BACKGROUND AND AIMS: In multiple sclerosis (MS), non-adherence/non-persistence is related to suboptimal response to treatment, including disease relapses and the need for more expensive healthcare. The aim of this study was to identify predictors related to adherence to disease modifying therapies (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zanga, Gisela, Drzewiscki, Estefania, Tagliani, Paula, Smietniansky, Maximiliano, Esnaola y Rojas, Maria M., Caruso, Diego
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8495537/ https://www.ncbi.nlm.nih.gov/pubmed/34630632 http://dx.doi.org/10.1177/17562864211031099

Ejemplares similares

Psychosocial predictors of patient adherence to disease-modifying therapies for multiple sclerosis
por: Alosaimi, Fahad D, et al.
Publicado: (2017)

Adherence to Disease-Modifying Therapies for Multiple Sclerosis
por: Higuera, Lucas, et al.
Publicado: (2016)

Predictors of duloxetine adherence and persistence in patients with fibromyalgia
por: Cui, Zhanglin, et al.
Publicado: (2012)

Adherence to disease-modifying therapies in patients with multiple sclerosis
por: Kołtuniuk, Aleksandra, et al.
Publicado: (2018)

Adherence to and Persistence with Disease-Modifying Therapies for Multiple Sclerosis Over 24 Months: A Retrospective Claims Analysis
por: Pardo, Gabriel, et al.
Publicado: (2022)

The Association Between Persistence and Adherence to Disease-Modifying Therapies and Healthcare Resource Utilization and Costs in Patients With Multiple Sclerosis
por: Pardo, Gabriel, et al.
Publicado: (2022)

Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data
por: Engmann, Natalie J, et al.
Publicado: (2021)

Medication adherence/persistence among patients with active multiple sclerosis in Finland
por: Lahdenperä, Sanni, et al.
Publicado: (2020)

Persistence to disease-modifying therapies for multiple sclerosis in a Canadian cohort
por: Melesse, Dessalegn Y, et al.
Publicado: (2017)

Adherence to disease-modifying treatments in patients with multiple sclerosis in Spain
por: Morillo Verdugo, Ramón, et al.
Publicado: (2019)

Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis
por: Halpern, Rachel, et al.
Publicado: (2011)

Use of an Early Disease-Modifying Drug Adherence Measure to Predict Future Adherence in Patients with Multiple Sclerosis
por: Kozma, Chris M., et al.
Publicado: (2014)

The Impact of Adherence to Disease-Modifying Therapies on Functional Outcomes in Veterans with Multiple Sclerosis
por: Rabadi, Meheroz H, et al.
Publicado: (2021)

Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review
por: Washington, Francesca, et al.
Publicado: (2021)

Association between multiple sclerosis disease severity and adherence to disease-modifying therapies
por: Burkhard, Adam, et al.
Publicado: (2021)

Comparative Adherence Trajectories of Oral Fingolimod and Injectable Disease Modifying Agents in Multiple Sclerosis
por: Earla, Jagadeswara R, et al.
Publicado: (2020)

Narrative Review of the Literature on Adherence to Disease-Modifying Therapies Among Patients with Multiple Sclerosis
por: Menzin, Joseph, et al.
Publicado: (2013)

Real-world adherence to, and persistence with, once- and twice-daily oral disease-modifying drugs in patients with multiple sclerosis: a systematic review and meta-analysis
por: Nicholas, Jacqueline A., et al.
Publicado: (2020)

Persistence, Adherence, and Switching to Higher-Cost Therapy in Patients with Multiple Sclerosis Initiating Oral Disease-Modifying Therapies: A Retrospective Real-World Study
por: Araujo, Lita, et al.
Publicado: (2022)

Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis
por: Lager, Brittney, et al.
Publicado: (2022)

Persistence and adherence in multiple sclerosis patients starting glatiramer acetate treatment: assessment of relationship with care received from multiple disciplines
por: Jongen, Peter Joseph, et al.
Publicado: (2016)

Multiple Sclerosis Patients Treated With Diroximel Fumarate in the Real-World Setting Have High Rates of Persistence and Adherence
por: Liseno, Jacob, et al.
Publicado: (2021)

Objective medication adherence and persistence in people with multiple sclerosis: a systematic review, meta-analysis, and meta-regression
por: Mardan, Joshua, et al.
Publicado: (2021)

Exercise Self-Efficacy and Fatigue as Predictors of Adherence to Home-Based Exercise Among Patients with Multiple Sclerosis
por: Almarwani, Maha, et al.
Publicado: (2023)

Adherence to Therapy in Patients with Multiple Sclerosis—Review
por: Kołtuniuk, Aleksandra, et al.
Publicado: (2022)

Adherence to Disease Modifying Drugs among Patients with Multiple Sclerosis in Germany: A Retrospective Cohort Study
por: Hansen, Kerstin, et al.
Publicado: (2015)

Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study
por: McKay, Kyla A, et al.
Publicado: (2016)

Impact of Adherence with Disease-Modifying Therapies on All-Cause Mortality Rates Among Veterans with Multiple Sclerosis
por: Rabadi, Meheroz H., et al.
Publicado: (2022)

Beliefs about medication as predictors of medication adherence in a prospective cohort study among persons with multiple sclerosis
por: Neter, Efrat, et al.
Publicado: (2021)

Predictors of Adherence Among Patients With Multiple Sclerosis Using the BETACONNECT(®) Autoinjector: A Prospective Observational Cohort Study
por: Köhler, Wolfgang, et al.
Publicado: (2021)

The Refinement of Genetic Predictors of Multiple Sclerosis
por: Disanto, Giulio, et al.
Publicado: (2014)

Predictors of vision impairment in Multiple Sclerosis
por: Sanchez-Dalmau, Bernardo, et al.
Publicado: (2018)

The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study
por: Beer, Karsten, et al.
Publicado: (2011)

The Impact of Comorbid Depression on Adherence to Therapy for Multiple Sclerosis
por: Tarrants, M., et al.
Publicado: (2011)

Factors Associated with Therapeutic Adherence in Multiple Sclerosis in Spain
por: Soria, Cristina, et al.
Publicado: (2023)

Adherence to Mediterranean Diet Is Associated with Multiple Sclerosis Severity
por: Guglielmetti, Monica, et al.
Publicado: (2023)

Disease Modifying Agents for Multiple Sclerosis
por: Hilas, Olga, et al.
Publicado: (2010)

Disease-modifying agents in multiple sclerosis
por: Coyle, P. K.
Publicado: (2009)

Disease Modifying Therapy in Multiple Sclerosis
por: Williams, U. E., et al.
Publicado: (2014)

Letter to the Editor Regarding: “Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis”
por: Nieto-Gómez, Pelayo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_658t6dn65qrao4f4742k7qncb6